

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**CHANGE OF JOINT COMPANY SECRETARY,
AUTHORIZED REPRESENTATIVE AND
AGENT FOR THE SERVICE OF PROCESS AND
NOTICES IN HONG KONG**

The board of directors (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Ms. Cheng Pik Yuk (“**Ms. Cheng**”) has resigned as a joint company secretary of the Company (the “**Joint Company Secretary**”) and ceased to act as an authorized representative of the Company (the “**Authorized Representative**”) as required under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and agent for the service of process and notices in Hong Kong (the “**Process Agent**”) under Rule 19.05(2) of the Listing Rules with effect from June 5, 2019.

Ms. Cheng has confirmed that there is no disagreement between herself and the Board and there are no other matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company.

The Board further announces that Ms. Sham Ying Man (“**Ms. Sham**”) has been appointed as the Joint Company Secretary, the Authorized Representative and the Process Agent in replacement of Ms. Cheng with effect from June 5, 2019. Mr. Huang Yue (“**Mr. Huang**”) will continue to act as the other Joint Company Secretary.

The biography of Ms. Sham is set out below:

Ms. Sham is a manager of Corporate Services of Tricor Services Limited, a global professional services provider specializing in integrated Business, Corporate and Investor Services. Ms. Sham has over 25 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Sham obtained a bachelor's degree in Business Administration from Lingnan College (now known as Lingnan University) in 1997. She is a Chartered Secretary and was admitted as an Associate of The Institute of Chartered Secretaries and Administrators in the United Kingdom in August 1993 and an Associate of The Hong Kong Institute of Chartered Secretaries in August 1994.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience.

Reference is made to the waiver granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the acting of Mr. Huang as the Joint Company Secretary of the Company for a period of three years from the date of appointment of Mr. Huang, being November 20, 2018 (the "**Waiver**"), on the condition that Mr. Huang will be assisted by Ms. Cheng, the Joint Company Secretary, during the waiver period to acquire the relevant experience as is required of a company secretary under Note 2 to Rule 3.28 of the Listing Rules and discharge his functions as the company secretary. The Waiver was revoked upon Ms. Cheng's resignation on June 5, 2019.

The Company has therefore applied to the Stock Exchange for, and the Stock Exchange has granted, a new waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Mr. Huang to act as a Joint Company Secretary of the Company (the “**New Waiver**”) from the date on which Ms. Sham was appointed as the other Joint Company Secretary of the Company, being June 5, 2019, to the remaining period of the Waiver (the “**New Waiver Period**”). The New Waiver is granted on the following conditions:

- (i) Mr. Huang will be assisted by Ms. Sham, the other Joint Company Secretary, during the New Waiver Period and the New Waiver will be revoked immediately if and when Ms. Sham ceases to provide assistance to Mr. Huang;
- (ii) the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that, after the end of the New Waiver Period, the Company will be able to demonstrate that Mr. Huang can satisfy the requirements under Rule 3.28 of the Listing Rules after having the benefit of Ms. Sham’s assistance such that a further waiver will not be necessary; and
- (iii) the Company will announce the details of the New Waiver, including its reasons and conditions.

The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its gratitude to Ms. Cheng for her valuable contribution to the Company during her tenure of service and extend its warm welcome to Ms. Sham for her new appointment.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 5, 2019

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*